Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1
A diabetes medication sustained improvements in cardiometabolic risk categories over 176 weeks, offering benefits beyond weight loss alone.
Post-hoc analysis of the Phase 3 SURMOUNT-1 trial (n=2,538) demonstrates that tirzepatide durably shifts WHtR risk categories, with 54.7% of treated participants improving WHtR category at 72 weeks versus 9.6% on placebo, and 16.7% achieving WHtR ≤0.49 (lowest cardiometabolic risk). Effects were sustained at 176 weeks in the prediabetes subgroup, supporting tirzepatide's cardiometabolic protective potential beyond weight reduction alone.
What the study was
- Study design
- Post-hoc analysis of Phase 3 double-blind RCT (SURMOUNT-1)
- Population
- Adults with obesity or overweight (BMI ≥27 with ≥1 complication) without diabetes; SURMOUNT-1 participants (n=2,538)
- Sample size
- 2538
- Category
- Prevention
- Maturity
- Validated
- Journal
- Journal of Endocrinological Investigation
Why it surfaced
Phase 3 post-hoc provides cardiometabolic risk categorization data supporting tirzepatide as more than a weight-loss agent; sustained WHtR benefit at 176 weeks strengthens durability claim. Eli Lilly-funded — note commercial interest.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.